Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback